Aveanna Healthcare Holdings sees $822,443 in stock sales by major owners

ATLANTA— Aveanna Healthcare Holdings , Inc. (NASDAQ:AVAH), a healthcare company with a market capitalization of $1.06 billion, recently reported a series of transactions involving the sale of its common stock by significant shareholders. According to the SEC filing, these sales amounted to a total of $822,443, with transaction prices ranging from $5.46 to $5.51 per share. InvestingPro data shows the stock has demonstrated remarkable performance, delivering a 117.53% return over the past year.

The transactions were carried out by several entities, including J.H. Whitney VII, L.P., PSA Healthcare Investment Holding LLC, JHW Iliad Holdings LLC, PSA Iliad Holdings LLC, and JHW Iliad Holdings II LLC. These entities are collectively managed by J.H. Whitney Capital Partners (WA:CPAP), LLC, with Paul R. Vigano serving as a key figure in their operations.

The sales were executed in accordance with a Rule 10b5-1 trading plan, which had been adopted on December 13, 2024. This plan allows insiders to set up a predetermined schedule for selling shares, providing a degree of protection against accusations of insider trading.

Following these transactions, the reporting entities still hold significant shares in Aveanna Healthcare, maintaining their status as major stakeholders. The sales were part of a broader strategy under the trading plan and do not necessarily reflect a change in their overall investment strategy in the company.

In other recent news, Aveanna Healthcare Holdings Inc. reported stronger-than-expected financial results for the fourth quarter of 2024. The company’s earnings per share (EPS) reached $0.05, surpassing the forecasted loss of $0.003, while revenue came in at $519.9 million, exceeding the anticipated $499.07 million. This performance highlights Aveanna’s strategic focus on enhancing its service offerings and expanding its payer agreements. Aveanna’s full-year 2024 revenue was $2.024 billion, marking a 6.8% increase year-over-year, with an adjusted EBITDA of $183.5 million, up 31.8% from the previous year.

In terms of future projections, Aveanna anticipates its 2025 revenue to be between $2.100 billion and $2.120 billion, with adjusted EBITDA expected to range from $190 million to $194 million. Additionally, UBS has updated its price target for Aveanna Healthcare, raising it to $4.50 from the previous $3.20, while maintaining a Sell rating on the company’s shares. These recent developments reflect Aveanna’s robust performance and strategic initiatives aimed at driving future growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.